Genedrive PLC says HCV test passes independent real-world study with flying colours
The study yielded sensitivity specifications of 96.2-100% and specificity specifications of 98.7-99.5% Genedrive PLC (LON:GDR) has announced the publication of a large independent multi-centre study evaluating the real-world performance of its HCV test in low and middle-income countries. The study yielded sensitivity specifications of 96.2-100% and specificity specifications of 98.7-99.5%, depending on the site or viral load, meaning the HCV -ID Kit is effective as intended in the diagnosis of HCV infection in resource-limited settings. The authors highlighted a test fail rate of 1.6%, whic...